IgA nephropathy
Conditions
Interventions
None listed
Sponsors
Viatris Pharmaceuticals Japan G.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with a confirmed diagnosis of IgA nephropathy by renal biopsy. 2. Japanese patients (regardless of gender) aged 18 years or older at the time of consent
Exclusion criteria
Exclusion criteria: 1. Patients currently receiving dialysis treatment. 2. Patients who have undergone renal transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Presence of (current) IgA nephropathy symptoms 2. Frequency of (current) IgA nephropathy symptoms 3. The impact of each symptom of IgA nephropathy on daily life (for each symptom) 4. The symptoms of IgA nephropathy that particularly affect daily life (rank the symptoms accordingly) 5. No longer able to do daily activities due to IgA nephropathy symptoms. 6. Symptoms of IgA nephropathy that would like to improve (rank the relevant symptoms) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Communication with doctors 2. Actual condition and intention of SDM 3. Satisfaction with treatment 4. Reasons for satisfaction with treatment 5. Sources of information on treatment 6. Information needed or lacking in treatment options 7. Ease of telling others about IgA nephropathy 8. Reasons for reluctance to tell others about IgA nephropathy | — |
Countries
Japan
Contacts
Public ContactTatsuya Ishikawa
3H Medi Solution Inc. Insight Solution Promotion Office
Outcome results
None listed